Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

摘要: Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas radiation. Gliomas express binding proteins, and cytotoxic concentrations metabolites are found in after oral administration. Twenty three patients, aged 25–78, new or recurrent were treated radiosurgery and/or radiotherapy. tumors Gamma Knife stereotactic radiosurgery; eligible limited 4 cm maximal diameter. newly diagnosed fractionated radiotherapy, also performed if tumor was less than Estramustine (16 mg/kg per day orally) started days prior radiosurgery, or, only radiotherapy performed, on first continued until completion (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of 13 patients for glioblastoma, median survival 16 months 38% 2-year survival. five 3, 8, 9, 15, 23+ months. Two anaplastic astrocytoma survived 24 48+ One patient mixed 5+ oligodendroglioma 20 42+ Four glioblastoma developed deep vein thrombosis. results this pilot study indicate some benefit, further investigation incorporating into clinical trials is suggested.